§814.1

- 814.42 Filing a PMA.
- 814.44 Procedures for review of a PMA.
- 814.45 Denial of approval of a PMA.
- 814.46 Withdrawal of approval of a PMA.
- 814.47 Temporary suspension of approval of a PMA.

Subpart D—Administrative Review [Reserved]

Subpart E—Postapproval Requirements

- 814.80 General.
- 814.82 Postapproval requirements.
- 814.84 Reports.

Subparts F-G [Reserved]

Subpart H—Humanitarian Use Devices

- 814.100 Purpose and scope.
- 814.102 Designation of HUD status.
- 814.104 Original applications.
- 814.106 HDE amendments and resubmitted HDE's.
- 814.108 Supplemental applications.
- 814.110 New indications for use.
- 814.112 Filing an HDE.
- 814.114 Timeframes for reviewing an HDE.
- 814.116 Procedures for review of an HDE.
- 814.118 Denial of approval or withdrawal of approval of an HDE.
- 814.120 Temporary suspension of approval of an HDE.
- $814.122\,$ Confidentiality of data and information.
- 814.124 Institutional Review Board requirements.
- 814.126 Postapproval requirements and reports.

AUTHORITY: 21 U.S.C. 351, 352, 353, 360, 360c-360j, 371, 372, 373, 374, 375, 379, 379e, 381.

Source: $51\ FR\ 26364$, July 22, 1986, unless otherwise noted.

Subpart A—General

§814.1 Scope.

- (a) This part implements section 515 of the act by providing procedures for the premarket approval of medical devices intended for human use.
- (b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.
- (c) This part applies to any class III medical device, unless exempt under section 520(g) of the act, that:
- (1) Was not on the market (introduced or delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not substan-

tially equivalent to a device on the market before May 28, 1976, or to a device first marketed on, or after that date, which has been classified into class I or class II; or

- (2) Is required to have an approved premarket approval application (PMA) or a declared completed product development protocol under a regulation issued under section 515(b) of the act; or
- (3) Was regulated by FDA as a new drug or antibiotic drug before May 28, 1976, and therefore is governed by section 520(1) of the act.
- (d) This part amends the conditions to approval for any PMA approved before the effective date of this part. Any condition to approval for an approved PMA that is inconsistent with this part is revoked. Any condition to approval for an approved PMA that is consistent with this part remains in effect.

§814.2 Purpose.

The purpose of this part is to establish an efficient and thorough device review process—

- (a) To facilitate the approval of PMA's for devices that have been shown to be safe and effective and that otherwise meet the statutory criteria for approval; and
- (b) To ensure the disapproval of PMA's for devices that have not been shown to be safe and effective or that do not otherwise meet the statutory criteria for approval. This part shall be construed in light of these objectives.

§814.3 Definitions.

For the purposes of this part:

- (a) *Act* means the Federal Food, Drug, and Cosmetic Act (sections 201–902, 52 Stat. 1040 *et seq.*, as amended (21 U.S.C. 321–392)).
- (b) *FDA* means the Food and Drug Administration.
- (c) *IDE* means an approved or considered approved investigational device exemption under section 520(g) of the act and parts 812 and 813.
- (d) *Master file* means a reference source that a person submits to FDA. A